Healio

Study: Ellipsoid zone a clinically relevant endpoint in AMD, GA trials

A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in ...
Enlace

Vértigo FX visual effects studio: the dream of Tijuana native...Vértigo FX visual effects studio: the dream of Tijuana native...

Report the Sale and Use of Fireworks During the Holiday Season in... Rosarito's Holiday Magic: Discover Traditions, Tastes, and Coastal... The Essential Rosarito Beach Dining Guide Everything You Need ...
Nasdaq

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint

Company to Host R&D Event on November 9th to Provide Detailed Review of Completed FX-322 Clinical Studies Supporting FX-322-208 Inclusion Criteria and Study Design LEXINGTON, Mass.--(BUSINESS WIRE)-- ...